- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07448610
Valutazione della sicurezza e dell'efficacia nel mondo reale dei partecipanti con atrofia muscolare spinale trattati con Onasemnogene Abeparvovec-brve intratecale (OAV101B) (ITVISMA®): uno studio pragmatico multicentrico negli Stati Uniti (STREAM)
Onasemnogene Abeparvovec: Valutazione della sicurezza ed efficacia nel mondo reale dei partecipanti affetti da atrofia muscolare spinale trattati con Onasemnogene Abeparvovec-brve intratecale (ITVISMA®): Uno studio pragmatico multicentrico negli Stati Uniti (STREAM)
The primary purpose is to address critical evidence in the treatment landscape for Spinal Muscular Atrophy (SMA), specifically focusing on the intrathecal formulation of onasemnogene abeparvovec-brve (ITVISMA®). U.S. Pragmatic Multicenter Study (STREAM).
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
STREAM is a prospective, multicentre cohort study that will follow U.S. participants with genetically confirmed SMA who receive a single, intrathecal dose of onasemnogene abeparvovec-brve. All eligible participants are enrolled prior to therapeutic injection. No randomisation, blinding, or placebo control is employed; instead, each participant acts as his or her own baseline comparator. This study will use an exploratory external cohort of patients matched by age, clinical characteristics, treatment history and availability of at least 1 year of pre-treatment medical history. This patient cohort will be based on a database of retrospectively collected electronic medical records data and will be used descriptively to contextualize study outcomes. Bias is minimised through pre-specified endpoints, uniform rater training on motor-function scales, and a detailed statistical analysis plan that stipulates handling of missing data and intercurrent events in advance.
Tipo di studio
Iscrizione (Stimato)
Fase
- Fase 4
Contatti e Sedi
Contatto studio
- Nome: Novartis Pharmaceuticals
- Numero di telefono: 1-888-669-6682
- Email: novartis.email@novartis.com
Backup dei contatti dello studio
- Nome: Novartis Pharmaceuticals
Luoghi di studio
-
-
Arkansas
-
Little Rock, Arkansas, Stati Uniti, 208833
- Reclutamento
- Arkansas Children's Hospital
-
Investigatore principale:
- Aravindhan Veerapandiyan
-
Contatto:
- Buffy Gofforth
- Numero di telefono: (501) 364-1591
-
-
California
-
Stanford, California, Stati Uniti, 94305-5235
- Reclutamento
- Stanford Hospital
-
Contatto:
- Numero di telefono: (650) 725-4341
- Email: NeuromuscularResearch@stanford.edu
-
Investigatore principale:
- John W Day
-
-
Massachusetts
-
Boston, Massachusetts, Stati Uniti, 02215
- Reclutamento
- Boston Childrens Hospital
-
Contatto:
- Maggie Allen
- Numero di telefono: (617) 919-3554
- Email: Maggie.Allen@childrens.harvard.edu
-
Investigatore principale:
- Leslie Hayes
-
-
New York
-
New York, New York, Stati Uniti, 10032
- Reclutamento
- Columbia University Medical Center
-
Investigatore principale:
- Claudia Chiriboga
-
Contatto:
- Kimberly Berry
- Numero di telefono: 212-342-3038
- Email: kb2996@cumc.columbia.edu
-
-
Ohio
-
Columbus, Ohio, Stati Uniti, 43210
- Reclutamento
- Ohio State University Medical Center
-
Investigatore principale:
- Bakri Elsheikh
-
Contatto:
- Georgia (Gia) Cinkay
- Numero di telefono: (614) 366-9050
- Email: Georgia.cinkay@osumc.edu
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Stati Uniti, 209277
- Reclutamento
- University of Pennsylvania
-
Investigatore principale:
- Lauren Elman
-
Contatto:
- Amanda (Mandy) Hicks
- Numero di telefono: (267) 496-3772
- Email: amanda.hicks@pennmedicine.upenn.edu
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Key Inclusion Criteria:
A participant will be enrolled in STREAM only if all the following conditions are met:
-
The participant has a genetically confirmed diagnosis of SMA (biallelic SMN1 deletion or mutation).
-
He or she is ≥ 2 years of age on the day of the intrathecal injection.
-
The treating Investigator intends to administer within the current episode of care, a single dose of ITVISMA® (1.2 × 10¹⁴ vg) in routine U.S. practice after written informed consent obtained.
-
One of the following functional categories applies at screening:
- independently ambulatory child/adolescent 2 - <18 years; or
- independently ambulatory adult (≥ 18 years).
- non-ambulatory (includes walkers with assistance) adult > 18 years with entry level RULM at baseline
-
At least 1 year of pre-treatment medical history, including motor-function documentation, can be retrieved from the site electronic record.
Key Exclusion Criteria:
A participant will be excluded if any of the following conditions apply:
- Contraindication for lumbar puncture as determined by the investigator (e.g., spinal anatomy that precludes safe lumbar puncture)
- An uncontrolled acute illness, active infection, febrile illness or acute medical condition, within 30 days prior to dosing
- Inability to tolerate corticosteroids administered by mouth or gastrostomy tube
- Current participation in another interventional clinical trial that would interfere with the objectives or endpoints of STREAM. Note: participation in observational cohort studies or non-interventional studies in which the participant does not receive treatment or undergo procedures which may compromise this study data integrity may be allowed following Sponsor approval
- Planned relocation or any circumstance that is likely to prevent completion of the minimum 12-month follow-up.
Other protocol inclusion, exclusion criteria may apply.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Onasemnogene Abeparvovec-brve
Participants with spinal muscular atrophy, including:
|
administered once via lumbar puncture with systemic corticosteroid prophylaxis per label.
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change from baseline in HFMSE for independently ambulatory participants
Lasso di tempo: Baseline, 6, 12, 18 and 24 months
|
The HFMSE is a validated SMA specific assessment devised for use in children with SMA to give objective information on motor ability and clinical progression. The HFMSE contains 33 items rated from 0 (unable to perform) to 2 (performs without modification/adaptation/compensation). Total scores range from 0-66. Higher scores indicate higher levels of motor ability. |
Baseline, 6, 12, 18 and 24 months
|
|
Change from baseline in RULM for non-ambulatory (including walkers with assistance) participants
Lasso di tempo: Baseline, 6, 12, 18 and 24 months
|
The RULM is a validated SMA specific assessment of motor performance in the upper limbs from childhood through adulthood in independent ambulatory and non-ambulatory (including walkers with assistance) individuals with SMA. The scale consists of 19 scorable items: 18 items scored on 0 (unable) to 2 (full achievement) scale, and one item that is scored from 0 (unable) to 1 (able). Total scores range from 0-37 points. Higher scores reflect higher level of motor ability. |
Baseline, 6, 12, 18 and 24 months
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Lasso di tempo: up to 5 years
|
Incidence of AEs and SAEs, including changes in laboratory tests and procedure-related events qualifying and reported as AEs. |
up to 5 years
|
|
Modified SMA Functional Rating Scale (SMA-FRS) for independently ambulatory participants (≥ 18 years of age) and non-ambulatory particpants
Lasso di tempo: Baseline, 6, 12, 18 and 24 months and Years 3, 4, and 5
|
Modified Spinal Muscular Atrophy Functional Rating Scale (SMAFRS): Ten items address questions related to eating, upper extremity dressing, lower extremity dressing, grooming, bathing, toileting, turning in bed and adjusting bed clothes, transfers, walking, and climbing stairs. This outcome measure includes effectiveness assessment across predefined participant groups based on relevant clinical and demographic factors, as specified in the protocol. |
Baseline, 6, 12, 18 and 24 months and Years 3, 4, and 5
|
|
Assessment of Caregiver Experience with Neuromuscular Disease (ACEND) for independently ambulatory participants (<18 years of age)
Lasso di tempo: Baseline, Months 6, 12, 18, 24, and Years 3, 4, and 5
|
The Assessment of Caregiver Experience with Neuromuscular Disease (ACEND): quantifies caregivers' perceptions of function and quality of life pertaining to time, finance and emotion. The ACEND was developed and validated to specifically assess caregiver impact experienced by raising children severely affected by neuromuscular diseases. While specifically developed for application to caregivers of patients undergoing orthopedic surgery, it has application to those with SMA. This outcome measure includes effectiveness assessment across predefined participant groups based on relevant clinical and demographic factors, as specified in the protocol. |
Baseline, Months 6, 12, 18, 24, and Years 3, 4, and 5
|
|
Subgroup outcomes: Hammersmith Functional Motor Scale Expanded (HFMSE)
Lasso di tempo: Baseline, 6, 12, 18 and 24 months
|
Effectiveness assessment across predefined participant groups based on relevant clinical and demographic factors, as specified in the protocol. The HFMSE is a validated SMA specific assessment to give objective information on motor ability and clinical progression. Total scores range from 0-66. Higher scores indicate higher levels of motor ability. |
Baseline, 6, 12, 18 and 24 months
|
|
Subgroup outcomes: Revised Upper Limb Module (RULM)
Lasso di tempo: Baseline, 6, 12, 18 and 24 months
|
Effectiveness assessment across predefined participant groups based on relevant clinical and demographic factors, as specified in the protocol. The RULM is a validated SMA specific assessment of motor performance in the upper limbs from childhood through adulthood in independent ambulatory and non-independent ambulatory individuals with SMA. Total scores range from 0-37 points. Higher scores reflect higher level of motor ability. |
Baseline, 6, 12, 18 and 24 months
|
|
Frequency of hospitalizations emergency department visits, outpatient visits, respiratory interventions and nutritional support interventions
Lasso di tempo: Baseline, Months 6, 12, 18, 24, and Years 3, 4, and 5
|
Assessment of SMA-related healthcare-resource utilisation. |
Baseline, Months 6, 12, 18, 24, and Years 3, 4, and 5
|
|
Duration of hospitalizations emergency department visits, outpatient visits, respiratory interventions and nutritional support interventions
Lasso di tempo: Baseline, Months 6, 12, 18, 24, and Years 3, 4, and 5
|
Assessment of SMA-related healthcare-resource utilisation. |
Baseline, Months 6, 12, 18, 24, and Years 3, 4, and 5
|
|
Cobb angle
Lasso di tempo: Baseline, up to 24 months
|
Assessment of scoliosis progression as a disease-progression marker. |
Baseline, up to 24 months
|
|
Daily hours of respiratory support (none, non-invasive ventilation, invasive ventilation)
Lasso di tempo: Baseline, up to 24 months
|
Assessment of respiratory function as a disease-progression marker. |
Baseline, up to 24 months
|
|
Joint-range limitation measured by goniometer
Lasso di tempo: Baseline, up to 24 months
|
Assessment of evolution of joint contractures as a disease-progression marker. |
Baseline, up to 24 months
|
|
Nutritional-support category (oral, gastrostomy feeds, total parenteral nutrition)
Lasso di tempo: Baseline, up to 24 months
|
Assessment of nutrition status as a disease-progression marker. |
Baseline, up to 24 months
|
|
6-Minute Walk Test (6MWT) for ambulatory patients
Lasso di tempo: Baseline, Months 6, 12, 18, and 24
|
To assess disease-progression markers. 6MWT: distance in metres; greater distance indicates better ambulatory capacity. |
Baseline, Months 6, 12, 18, and 24
|
Collaboratori e investigatori
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- COAV101B1US01
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .